TICKERNERD
Menu
GNPXGNPXHealthcare · Biotechnology

GNPX Stock Forecast: Genprex, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$2.14

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 4 Nov 2026 — in the weakest quartile.

Market cap
$1.9M
Ticker Nerd rank
12/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$4.5M
Net income−$4.4M
Free cash flow−$5.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

GNPX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Genprex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
12/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Volatility
61
Growth
43
Accruals
34
Revisions
25
Issuance
23
Quality
18
Value
8
Momentum
2

Size (98): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GNPX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNPX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 May 2024HC Wainwright & Co.ReiteratesBuy$10
15 May 2024HC Wainwright & Co.ReiteratesBuy$10
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Mar 2024HC Wainwright & Co.InitiatesBuy—
30 Jan 2023Dawson JamesInitiatesBuy$3.00
14 Sept 2018Maxim GroupInitiatesBuy$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GNPX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

GNPX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Genprex, Inc. (GNPX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
0.9×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−203.9%

Higher than 7% of US stocks

Return on assets
−94.5%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Genprex, Inc. (GNPX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Genprex, Inc. has a market value of $1.9M and an enterprise value of −$13.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$15.6M.

  • Shares outstanding: 504,935.

  • Trailing P/E: 0.1×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Genprex, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

GNPX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNPXGenprex, Inc.$1.9M12
XRTXXORTX Therapeutics, Inc.$1.8M12
GOVXGeoVax Labs, Inc.$1.7M26
PPCBPropanc Biopharma, Inc.$1.8M47
KAPAKairos Pharma Ltd.$1.7M35
KPTIKaryopharm Therapeutics, Inc.$1.6M66
VRAXVirax Biolabs Group Ltd.$1.6M15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Genprex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GNPX news & analysis

Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer

PRNewsWire · 4 Nov 2026positive

Genprex announced research identifying TROP2 expression as a potential predictive biomarker for response to Reqorsa in non-small cell lung cancer. The preclinical findings associated low TROP2 expression with resistance to Reqorsa; the research is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium.

Why it matters — The findings may inform future patient selection for Reqorsa, though they are based on preclinical models.

Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting

PRNewsWire · 28 Oct 2026positive

Genprex said research from its sponsored collaboration with Meharry Medical College will be presented at the Gerontological Society of America’s 2026 Annual Scientific Meeting. The research examines TUSC2’s role in mitochondrial biology, cellular resilience, and molecular processes associated with aging.

Why it matters — The presentation discusses investigation of TUSC2 and potential applications beyond oncology, relevant to Genprex’s research program.

Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging

PRNewsWire · 21 Oct 2026positive

Genprex highlighted a peer-reviewed mouse study by Meharry Medical College researchers finding that TUSC2 loss has sex-specific effects on mitochondrial function, protein homeostasis and synaptic pathways in the aging hippocampus. The study also reported molecular similarities with the human brain.

Why it matters — TUSC2 is the gene used in Genprex’s REQORSA, and the findings add research on its potential role in cellular processes linked to brain health and aging.

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 8 Sept 2026neutral

Genprex, Inc. announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference. The company presentation will highlight its lead clinical oncology program and preclinical diabetes program.

Why it matters — The presentation gives Genprex watchers a potential opportunity to hear directly from leadership about the company's clinical oncology and preclinical diabetes programs at a major investment conference.

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

PRNewsWire · 18 Aug 2026positive

Genprex announced it has entered into a development and manufacturing agreement with a leading U.S.-based clinical and commercial CDMO to initiate manufacturing scale-up of its diabetes gene therapy program. The collaboration is intended to accelerate manufacturing processes for IND-enabling preclinical studies and future clinical trials, allowing the therapeutic candidate to transition from research-grade production to clinical and commercial-ready output.

Why it matters — GNPX watchers would care because the agreement moves the company's diabetes gene therapy candidate toward clinical and commercial-ready production, a key step in advancing the program toward IND-enabling studies and future clinical trials.

FAQ

Frequently asked questions about GNPX stock

Is GNPX stock a buy right now?

Of the 1 analysts covering Genprex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genprex, Inc. 12 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNPX?

As at 4 Nov 2026, Genprex, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the GNPX stock forecast for 2030?

No analyst covering Genprex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNPX are extrapolating price history, which says nothing about the business.

What does Genprex, Inc. do?

Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes.

What is the latest news on GNPX?

The most recent item we track (PRNewsWire, 4 Nov 2026): "Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer". Genprex announced research identifying TROP2 expression as a potential predictive biomarker for response to Reqorsa in non-small cell lung cancer. The preclinical findings associated low TROP2 expression with resistance to Reqorsa; the research is scheduled for presentation at the 2026 EORTC-NCI-AACR Symposium.

Company

About Genprex, Inc.

Genprex Inc. Common Stock is the equity security of Genprex Inc., a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The company’s current pipeline centers on gene-based technologies designed to deliver therapeutic genes using non-viral and nanoparticle delivery approaches. Its oncology work includes REQORSA immunogen therapy, which is being developed for lung cancer, while its diabetes program includes GPX-002, a gene therapy candidate aimed at addressing metabolic disease. Genprex Inc. operates in the healthcare and biotechnology sectors, where it contributes to the broader field of advanced genetic medicine and targeted treatment development. The common stock represents investor exposure to a company whose business is built around translational research, drug development, and clinical-stage innovation in diseases with significant unmet medical need.

CEO Mr. Ryan M. Confer M.S. · 13 employees · United States · https://www.genprex.com